Tafasitamab
Based on 2 publication(s) in Google Scholar
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 1422527-84-1
- Molecular Weight:147.42 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tafasitamab
More
Biological Activity
Human IgG1 kappa
Human
CD19
Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NHL cell lines and primary CLL and MCL cells by γδ T cells
-
Concentration:
-
Incubation Time:2 h
-
Result:Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.
-
Cell Line:SU-DHL-6 cells
-
Concentration:
-
Incubation Time:72 h
-
Result:Showed potent antiproliferative effects on tumor cell.
-
Cell Line:SU-DHL-6 cells
-
Concentration:0-4 ng/mL
-
Incubation Time:48 h
-
Result:Showed potent antiproliferative effects due to caspase-induced apoptosis
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Disseminated Raji model[1].
-
Dosage:2.5 μg/kg
-
Administration:Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
-
Result:Showed antitumor activity in disseminated Raji model.
-
Animal Model:Disseminated Ramos model[1].
-
Dosage:10 mg/kg
-
Administration:Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
-
Result:Showed antitumor activity in disseminated Ramos model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-G2-kappa
ELISA, FACS, Functional assay
-
Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC50 for this effect is 29.1 ng/mL. -
Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 95.42 and 117.87 ng/mL.
Chemical Information
-
CAS No. 1422527-84-1
-
Appearance Liquid
-
Molecular Weight 147.42 kDa
-
Color Colorless to light yellow
-
SMILES
[Tafasitamab]
-
Synonyms
XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Clin Chem Lab Med
2025 Sep 15. PMID: 40965972 -
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [Content Brief]
[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz